Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Enliven Therapeutics ( (ELVN) ) just unveiled an announcement.
On January 6, 2026, Enliven Therapeutics’ board appointed veteran biopharma executive Scott Garland as a Class I director and Chair of the Nominating and Corporate Governance Committee, effective January 7, 2026, while long-serving director Andrew Phillips, Ph.D., resigned from the board and its committees effective the same date, with the company emphasizing that his departure was not due to any disagreement over operations, policies or practices. Garland, who had consulted for Enliven since January 2024 and brings more than 30 years of commercial leadership experience in oncology and hematology, joins the board as the company pivots from early-stage development to late-stage development and potential commercialization of its lead candidate ELVN-001, following positive clinical data reported in 2025 and in anticipation of initiating a pivotal Phase 3 trial in chronic myeloid leukemia in 2026, a shift that underscores Enliven’s effort to reinforce its leadership and governance for its next phase of growth.
The most recent analyst rating on (ELVN) stock is a Hold with a $15.50 price target. To see the full list of analyst forecasts on Enliven Therapeutics stock, see the ELVN Stock Forecast page.
Spark’s Take on ELVN Stock
According to Spark, TipRanks’ AI Analyst, ELVN is a Neutral.
The score is driven primarily by weak financial performance (pre-revenue, widening losses, and sustained cash burn) despite a strong, low-leverage balance sheet. Technicals add pressure with a clear downtrend and weak momentum. Valuation is constrained by negative earnings, while the leadership change is a modest positive but secondary to the financial and technical risks.
To see Spark’s full report on ELVN stock, click here.
More about Enliven Therapeutics
Enliven Therapeutics, based in Boulder, Colorado, is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule precision oncology therapies aimed at addressing unmet needs, improving survival and enhancing quality of life, with its lead program ELVN-001 targeting chronic myeloid leukemia.
Average Trading Volume: 634,953
Technical Sentiment Signal: Sell
Current Market Cap: $902.7M
See more data about ELVN stock on TipRanks’ Stock Analysis page.